Skip to main content

Fiscal Wizard · Single-issue tearsheet

ELOX / Jun 21, 2026 Run #7474

ELOX

Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Composite verdict

F 25.5 / 100
Gated stand-aside 0 drivers · 6 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 204th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

25.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 100
Free Cash Flow Yield 0
Greenblatt EY 66
Revenue Growth (YoY) 0
Return on Assets 7

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

6 blocking 1 caution

6 guards active, 39 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for ELOX.